Premenstrual Dysphoric Disorder (PMDD) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: PF135D8B0E42EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Premenstrual Dysphoric Disorder (PMDD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Premenstrual Dysphoric Disorder (PMDD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Premenstrual Dysphoric Disorder (PMDD) Understanding

The DelveInsight Premenstrual Dysphoric Disorder (PMDD) epidemiology report gives a thorough understanding of the Premenstrual Dysphoric Disorder (PMDD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Premenstrual Dysphoric Disorder (PMDD) in the US, Europe, and Japan. The report covers the detailed information of the Premenstrual Dysphoric Disorder (PMDD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Premenstrual Dysphoric Disorder (PMDD) Epidemiology Perspective by DelveInsight

The Premenstrual Dysphoric Disorder (PMDD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Premenstrual Dysphoric Disorder (PMDD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Premenstrual Dysphoric Disorder (PMDD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Premenstrual Dysphoric Disorder (PMDD) Detailed Epidemiology Segmentation

The Premenstrual Dysphoric Disorder (PMDD) epidemiology covered in the report provides historical as well as forecasted Premenstrual Dysphoric Disorder (PMDD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Premenstrual Dysphoric Disorder (PMDD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Premenstrual Dysphoric Disorder (PMDD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Premenstrual Dysphoric Disorder (PMDD) Epidemiology Report and Model provide an overview of the global trends of Premenstrual Dysphoric Disorder (PMDD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Premenstrual Dysphoric Disorder (PMDD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Premenstrual Dysphoric Disorder (PMDD)
• The report provides the segmentation of the Premenstrual Dysphoric Disorder (PMDD) epidemiology

Report Highlights

• 11-year Forecast of Premenstrual Dysphoric Disorder (PMDD) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Premenstrual Dysphoric Disorder (PMDD)
• Cases of Premenstrual Dysphoric Disorder (PMDD) by Mutation Types
• Premenstrual Dysphoric Disorder (PMDD) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Premenstrual Dysphoric Disorder (PMDD)?
• What are the key findings pertaining to the Premenstrual Dysphoric Disorder (PMDD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Premenstrual Dysphoric Disorder (PMDD) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Premenstrual Dysphoric Disorder (PMDD)?
• What are the currently available treatments of Premenstrual Dysphoric Disorder (PMDD)?

Reasons to buy

The Premenstrual Dysphoric Disorder (PMDD) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Premenstrual Dysphoric Disorder (PMDD) market
• Quantify patient populations in the global Premenstrual Dysphoric Disorder (PMDD) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Premenstrual Dysphoric Disorder (PMDD) therapeutics in each of the markets covered
• Understand the magnitude of Premenstrual Dysphoric Disorder (PMDD) population by its epidemiology
• The Premenstrual Dysphoric Disorder (PMDD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD)

3. PREMENSTRUAL DYSPHORIC DISORDER (PMDD): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Premenstrual Dysphoric Disorder (PMDD) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Premenstrual Dysphoric Disorder (PMDD) Treatment and Management
6.2. Premenstrual Dysphoric Disorder (PMDD) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in 7MM (2019-2032)
Table 2: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in the United States (2019-2032)
Table 4: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Germany (2019-2032)
Table 6: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in France (2019-2032)
Table 8: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Italy (2019-2032)
Table 10: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Spain (2019-2032)
Table 12: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Japan (2019-2032)
Table 16: Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in 7MM (2019-2032)
Figure 2 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in the United States (2019-2032)
Figure 4 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Germany (2019-2032)
Figure 6 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in France (2019-2032)
Figure 8 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Italy (2019-2032)
Figure 10 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Spain (2019-2032)
Figure 12 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Premenstrual Dysphoric Disorder (PMDD) Epidemiology in Japan (2019-2032)
Figure 16 Premenstrual Dysphoric Disorder (PMDD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report